Teva Pharmaceutical Industries Q2 2026 Earnings Report

Teva Pharmaceutical Industries EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.39
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Teva Pharmaceutical Industries Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $4.05 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Teva Pharmaceutical Industries Announcement Details

• Quarter: Q2 2026
• Date: 7/29/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, July 29, 2026
• Conference Call Time: 8:00AM ET

Teva Pharmaceutical Industries (NYSE:TEVA) (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease. Its specialty portfolio is best known for Copaxone (glatiramer acetate), a long‑standing therapy for multiple sclerosis, while the broader business includes complex generics, emerging biosimilars, innovative formulations and pipeline programs. The company also offers contract manufacturing, licensing and distribution services and maintains R&D capabilities focused on generic product development and targeted specialty therapeutics.

Headquartered in Petah Tikva, Israel, Teva has grown through a combination of organic expansion and acquisitions and serves customers across North America, Europe, Latin America, Asia Pacific and other regions. The company is overseen by a board of directors and an executive management team responsible for global operations, regulatory compliance and commercial strategy. Teva’s strategic priorities include scaling its generic offerings, advancing selected specialty programs and pursuing operational efficiencies to support its extensive international footprint.